Tacrolimus and diarrhea: Pathogenesis of altered metabolism

Pediatric Transplantation

Volumn 5, Issue 2, 2001, Pages 75-79

  Mittal, Naveen ^a   Thompson, John F ^a   Kato, Tomoaki ^a   Tzakis, Andreas G ^a  

^a Department of Surgery ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; GLYCOPROTEIN P; TACROLIMUS;

ACUTE GASTROENTERITIS; CASE REPORT; CHILD; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG METABOLISM; EDITORIAL; HUMAN; ORGAN TRANSPLANTATION; PATHOGENESIS; ROTAVIRUS;

DIARRHEA; DRUG MONITORING; GASTROENTERITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; ROTAVIRUS INFECTIONS; TACROLIMUS; TRANSPLANTATION;

EID: 0035047682     PISSN: 13973142     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3046.2001.005002075.x     Document Type: Editorial

References (27)

1. Two-year experience with FK 506 in pediatric patients
2. FK506 (tacrolimus) compared with cyclosporine for primary immunosuppression after pediatric liver transplantation. Results from the US multicenter trial
3. Rotavirus infection as cause of tacrolimus elevation in solid-organ-transplanted children
4. Apparently increased through levels of tacrolimus caused by acute infantile diarrhea in two infants with biliary atresia after liver transplantation
5. Increased tacrolimus levels in a pediatric renal transplant patient attributed to chronic diarrhea
6. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery
7. CYP3A gene expression in human gut epithelium
8. Metabolism of the macrolide immunosuppressants, tacrolimus, by the pig gut mucosa in the Ussing chamber
9. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics
10. P-glycoprotein and drug therapy in organ transplantation
11. The P450 superfamily: Update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature
12. Differences in oral FK506 dose requirements between adult and pediatric liver transplant patients
13. Increased clearance of tacrolimus in children: Need for higher doses and earlier initiation prior to bone marrow transplantation
14. Modulators and substrates of P-glycoprotein and cytochrome P450 3A coordinately up-regulate these proteins in human colon carcinoma cells
15. Overlapping substrate specificity and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
16. Pharmacological insights from P-glycoprotein knockout mice
17. Role of intestinal P-glycoprotein (mdr1) in interpatient variations in the oral bioavailability of cyclosporine A
18. Clinical pharmacokinetics of tacrolimus
19. Effects of intestinal and hepatic metabolism on the bioavailability of tacrolimus in rats
20. Differential trophism of EB rotavirus (serotype 3) to small intestine of homologous murine model
21. Pseudomembranous viral colitis
22. The effect of tacrolimus (FK506) on intestinal barrier function and cellular energy production in humans
23. Hepatic involvement in rotavirus gastroenteritis in a homologous murine model
24. Extra-intestinal rotavirus infection in children with immunodeficiency
25. Clinical features of nosocomial rotavirus infection in pediatric liver transplant recipients
26. Pharmacokinetics of tacrolimus and cyclosporine in short-bowel syndrome
27. Individual variation in intestinal mdr 1 expression: Lack of short-term diet effects